Lymphoma Working Group
The AMC has implemented and completed several seminal studies which have clearly changed the way in which patients with AIDS-related lymphoma (ARL) are treated, moving the field forward in a step-wise manner over the years, with the results of one study leading us toward the next hypotheses, studies and results. The modest effects of HAART on cyclophosphamide clearance suggested that careful monitoring should be incorporated into trials using higher doses of cyclophosphamide, as in the transplant setting. Nonetheless, the study showed that combination chemotherapy could be used safely with concomitant HAART.
The current goals of the Lymphoma WG are to:1. Determine the optimal treatment of patients with AIDS-related lymphoma and Hodgkin’s disease, within the context of highly active anti-retroviral therapy.
2. Determine biologic correlates of disease and of response to therapy in patients with AIDS-related lymphoma and HD, in order to ascertain future targets for development and testing of innovative new therapies for affected patients.
3. Determine any biologic or clinical differences between AIDS-related Burkitt’s lymphoma when diagnosed in the USA versus other regions of the world.
Current Protocols: